PROGRAM (Download PDF)

Tuesday 28 September 2010


08.30 - 09.00


Arrival and Registration on 1st floor (Posters on 3rd floor)

SESSION I

Molecular Biology of Kv7 Modulation

(Chairs: Thomas Jentsch and Rob Towart)

09.00 - 09.05

Welcome and Opening Remarks

(Organizing Committee)

09.05 - 09.15

Kv7 modulation in preclinical and clinical settings: An overview
William Dalby-Brown (NeuroSearch A/S)

09.15 - 10.00

M-channels: thirty years of progress (1980-2010) (Keynote Speech)
David A. Brown (University College London, UK)

10.00 - 10.30

Molecular pharmacology of M-channels
Eva Wrobel (Ruhr University Bochum, Germany)

10.30 - 11.00

Break (Coffee and tea, 3rd floor)

11.00 - 11.30

Mechanisms for Kv7 trafficking to the cell surface
Alvaro Villaroel (Universidad del País Vasco, Leioa, Spain)

11.30 - 11.45

Mechanisms of M-channel localization at the axon initial segment
Hanne B. Rasmussen (University of Copenhagen, Norway)

11.45 - 12.15

M-channel functions in cortical neurons
Johan Storm (University of Oslo, Norway)

12.15 - 12.45

Structure-function analysis of Kv7 channel gating: lessons from Benign Familial Neonatal Convulsions (BFNC)
Maurizio Taglialatela (University of Molise, Italy)

12.45 - 13.30

Lunch:bio-organic Danish "open sandwiches" (3rd floor)


SESSION II

Effects of Kv7 modulation: translation from non-clinic to the clinic

(Chairs: David A Brown and Darrel J Pemberton)


13.30 - 14.00


Retigabine: a first in class Kv7 channel opener, filed for the adjunctive treatment of epilepsy partial seizures
Martin Gunthorpe (GlaxoSmithKline, Harlow, UK)

14.00 - 14.45

Kv7 Behavioural Pharmacology: Translation from Preclinical Potential to Clinical Efficacy?
Bob McArthur (McArthur and Associates GmbH, Basel, Switzerland)

14.45 - 15.15

Break (Coffee and tea, 3rd floor)

15.15 - 16.00

How Animal Models Predict Clinical Efficacy: Examples from the Past
Peter de Boer (Janssen Pharmaceutica NV, Belgium)

16.00 - 16.30

Side Effects of Kv7.1 (IKs) channel blockade: Emphasises Need for Specificity!
Rob Towart (Janssen Pharmaceutica NV, Belgium)

16.30 - 17.00

New Tricks for Old Dogs: Kv7 Expression and its Role in Smooth Muscle
Iain Greenwood (University of London, UK)

17.00 - 17.15

Final remarks

17.15 -

Social event: Copenhagen Canal Tour (Walk - 600 m from Venue) then dinner at "Madklubben", Store Kongensgade 66, DK-1264 (http://www.madklubben.info/main.aspx)



Wednesday 29 September 2010


08.30 - 09.00


Arrival (Posters on 3rd floor)

SESSION III

Dopamine modulation by Kv7 activation

(Chairs: Alvaro Villaroel and Henrik Sindal Jensen)

09.00 - 09.05

Welcome and opening remarks

(Organizing Committee)

09.05 - 09.25

Complexity of brain regional Kv7 channel expression and the interaction with dopaminergic neurotransmission
Henrik Hansen (NeuroSearch A/S)

09.25 - 09.35

Discussion

09.35 - 10.00

Effects of modulators of the M-current on dopamine neuron excitability
Vincent Seutin (University of Liège, Belgium)

10.00 - 10.15

Discussion

10.15 - 10.45

Break (Coffee and tea, 3rd floor)

10.45 - 11.05

KCNQ (Kv7) channels control the nigro-striatal dopaminergic pathway in the mammalian brain
Jens D. Mikkelsen (University hospital Copenhagen, Denmark)

11.05 - 11.15

Discussion

11.15 - 11.45

Modulation of dopamine function by retigabine: therapeutic implications
Florence Sotty (H. Lundbeck A/S)

11.45 - 12.15

Panel discussion: Lessons learned and gaps in understanding of dopamine modulation by Kv7 activation/inhibition

12.15 - 14.00

Lunch and poster session (3rd floor)


SESSION IV

Physiological role of individual subtypes and obtaining pharmacological selectivity

(Chairs: Johan Storm and William Dalby-Brown)

14.00 - 14.20

How can we achieve a detailed structural understanding of M-channel modulation to aid the development of better drugs?
Guiscard Seebohm (Ruhr University Bochum, Germany)

14.20 - 14.30

Discussion

14.30 - 15.00

Roles of KCNQ4 and KCNQ5 Investigated by Mouse Models
Thomas J. Jentsch (FMP (Leibniz-Institut fuer Molekulare Pharmakologie) and MDC (Max-Delbrueck-Centrum fuer Molekulare Medizin), Berlin, Germany)

15.00 - 15.10

Discussion

15.10 - 15.20

Stretch your legs coffee break

15.20 - 15.40

Pharmacological modulation of Kv7-channel biophysical parameters - comparing Kv7.2 and Kv7.4
Sigrid Blom (H. Lundbeck A/S)

15.40 - 15.50

Discussion

15.50 - 16.10

Subtype-selective pharmacological tools. What can they tell us about the functional significant Kv7 subtypes in brain slices ?
Charlotte Hougaard (NeuroSearch A/S)

16.10 - 16.20

Discussion

16.20 - 16.50

Targeting the voltage sensor of Kv7.2 channels with new gating-modifiers
Bernard Attali (Sackler Medical School, Tel Aviv University, Israel)

16.50 - 17.00

Discussion

17.00

Close of Meeting and Final Remarks

17.00 - 18.30

Beer Session: Relax and enjoy a soda or beer with your fellow colleagues (3rd floor)